Home Cart Sign in  
Chemical Structure| 136236-51-6 Chemical Structure| 136236-51-6

Structure of Rasagiline
CAS No.: 136236-51-6

Chemical Structure| 136236-51-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Rasagiline is an irreversible, potent and highly selective MAO-B inhibitor used to treat symptoms in early Parkinson's disease.

Synonyms: (R)-AGN1135; TVP1012; Azilect, HSDB 7699, Rasagiline, TV 1030, TV-1030

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Rasagiline

CAS No. :136236-51-6
Formula : C12H13N
M.W : 171.24
SMILES Code : [C@@H]1(C2=C(CC1)C=CC=C2)NCC#C
Synonyms :
(R)-AGN1135; TVP1012; Azilect, HSDB 7699, Rasagiline, TV 1030, TV-1030
MDL No. :MFCD00866571
InChI Key :RUOKEQAAGRXIBM-GFCCVEGCSA-N
Pubchem ID :3052776

Safety of Rasagiline

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • MAO-B

    MAO-B, IC50:4.43 nM

  • MAO-A

    MAO-A, IC50:412 nM

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01652313 Parkinson's Disease PHASE1 COMPLETED - CN001, Beijing, China
NCT00755027 Parkinson's Disease PHASE4 COMPLETED 2025-06-14 Fundacio de Gestio Sanitaria d... More >>e l'Hospital de la Santa Creu i Sant Pau, Barcelona, 08025, Spain Less <<
NCT02278588 Parkinson's Disease COMPLETED 2025-12-17 University at Buffalo, Buffalo... More >>, New York, 14214, United States Less <<
NCT00104273 Dementia|Alzheimer's Disease PHASE2 COMPLETED - Collaborative Neuroscience Net... More >>work, Huntsville, Alabama, 35801, United States|North Alabama Neuroscience Research, Huntsville, Alabama, 35801, United States|Northwest Neurospecialists, PLLC, Tucson, Arizona, 85741-3537, United States|Clinical Study Centers, LLC, Little Rock, Arkansas, 72205, United States|East Bay Region Associates in Neurology, Berkeley, California, 94705, United States|Margolin Brain Institute, Fresno, California, 93720, United States|Collaborative Neuroscience Network, Garden Grove, California, 92845, United States|San Francisco Clinical Research Center, San Francisco, California, 94109, United States|Neurological Research Institute, Santa Monica, California, 90404, United States|University of Colorado Health Sciences Center, Denver, Colorado, 80262, United States|Premiere Research Institute, West Palm Beach, Florida, 33407, United States|North Broward Medical Center/Memory Disorder Center, West Palm Beach, Florida, 33409, United States|Emory University Wesley Woods Health Center, Altanta, Georgia, 30329, United States|Dekalb Neurology Associates, LLC, Decatur, Georgia, 30033, United States|Radiant Research, Chicago, Illinois, 60610, United States|Fort Wayne Neurological Center, Fort Wayne, Indiana, 46805, United States|Mid America Neuroscience Institute, Lenexa, Kansas, 66214, United States|Four Rivers Clinical Research, Paducah, Kentucky, 42003, United States|Tulane University Health Sciences Center, Dept of Psychiatry and Neurology, New Orleans, Louisiana, 70112, United States|Department of Neurology - Brigham and Women's Hospital, Boston, Massachusetts, 02115, United States|Northern Michigan Neurology, Traverse City, Michigan, 49684, United States|University Behavioral Healthcare Centre Department of Psychiatry, Piscataway, New Jersey, 08854, United States|Odyssey Research, Fargo, North Dakota, 58104, United States|Ohio State University, Department of Neurology, Columbus, Ohio, 43210, United States|Pahl Brain Associates, Oklahoma City, Oklahoma, 73118, United States|Medical University of South Carolina Alzheimer's Research and Clinical Programs, North Charleston, South Carolina, 29406-6076, United States|Department of Neurology Baylor College of Medicine, Houston, Texas, 77030-2744, United States|Premiere Research Institute, Houston, Texas, 77030, United States|University of Texas Mental Sciences Institute, Houston, Texas, 77030, United States|Peninsula Internal Medicine Associates, Gig Harbor, Washington, 98335, United States|Internal Medicine Northwest, Tacoma, Washington, 98405, United States|Ballarat Health Service - Queen Elizabeth Center, Ballarat, 3350, Australia|Aged Mental Health Research Unit - Kingston Centre, Cheltenham, 3192, Australia|Prince Charles Hospital - Dept. of Geriatrics, Chermside, QLD4032, Australia|Central Coast Neuroscience Research, East Gosford, NSW 2250, Australia|Heidelberg Repatriation Hospital, Heidelberg West, 3081, Australia|Hornsby Kur-ing-gai Hospital, Rehabilitation and Aged Care Service, Hornsby, 2076, Australia|St. George's Hospital, Kew, 3101, Australia|McCusker Foundation for Alzheimer's Disease Research, Nedlands, 6009, Australia|The Queen Elizabeth Hospital, Woodville, 5011, Australia|Glenrose Rehabilitation Hospital, Edmonton, Alberta, T5G 0B7, Canada|Memory Disorder Clinic/Winnipeg Clinic, Winnipeg, Manitoba, R3C 0N2, Canada|Dept. of Clinical Neurological Sciences - University of Western Ontario, London, Ontario, N6A 4V2, Canada|155974 Ont. Inc., Peterborough, Ontario, K9H 2P4, Canada|Neurology Research Inc., Toronto, Ontario, M3B 2W7, Canada|Bloemfontein Medi Clinic, Westdene, Bloemfontein, 9301, South Africa|Westdene Research Centre, Westdene, Bloemfontein, 9301, South Africa|Suite C, Black C, Sandton, Gauteng, 2196, South Africa|St. Augustine's Medical Mews., Durban, 4001, South Africa|The Memory Centre, Johannesburg, 2197, South Africa|Dr. Felix Potocnik, Oakdale, 7530, South Africa|Panorama Medical Centre, Panorama, 7500, South Africa|Milpark Hospital, Parktown, 2193, South Africa|Crompton Medical Centre West, Pinetown, 3610, South Africa|Constantiaberg Medi Clinic, Plumstead, 7800, South Africa|Willows Medical Center, Pretoria, 0041, South Africa|Little Company of Mary Hospital, Pretoria, 0181, South Africa|Richard's Bay Trial Centre, Richard's Bay, 3900, South Africa Less <<
NCT05611372 REM Sleep Behavior Disorder|Pa... More >>rkinson Disease|Synucleinopathies Less << PHASE2|PHASE3 WITHDRAWN 2026-12-31 -
NCT03727139 Parkinson's Disease COMPLETED 2021-10-31 Takeda Selected Site, Tokyo, J... More >>apan Less <<
NCT01178047 Parkinson's Disease PHASE4 TERMINATED 2025-10-12 University Hospital, Neurology... More >>, Zurich, ZH, CH-8091, Switzerland|Neurocentro, Lugano, Lugano, Switzerland Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

5.84mL

1.17mL

0.58mL

29.20mL

5.84mL

2.92mL

58.40mL

11.68mL

5.84mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories